Neurodegenerative disease is an umbrella term for a range of conditions that result in progressive degeneration and premature death of neurons (nerve cells) in the body. Neurons, being the basic building block of the nervous system, is responsible for receiving, transmitting and communicating information between different cells and neurons in the body. Neurons are not easily reproduced or replaced when thy die or become damaged.
Among neurodegenerative diseases, Alzheimer’s (AD) and Parkinson’s (PD) are the top two commonly diagnosed diseases. Parkinson’s disease symptoms are basically related to movement disorders including trembling of hands, arms and legs and slowness of movement, whereas Alzheimer’s disease symptoms are associated with dementia resulting in memory loss and difficulties in speaking, reading and writing. To date, drugs market is dominated by symptom-relief drugs and there is limited treatment to slow, stop or modify the progression of Parkinson’s, Alzheimer’s and other neurodegenerative diseases.
FHL has developed an extraordinary portfolio of 8 drug candidates and combo drugs for neurodegenerative diseases, initially focused on Parkinson’s, that are potential to slow or reverse the disease progression and improve patient’s lives.
With the adoption of precision-medicine and patient-focused model, FHL plans to establish robust patient recruitment criteria to select and enrol right target groups based on objective measures for the disease progression .